Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-11-07
DOI
10.1111/dom.15318
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials
- (2022) Junaid Iqbal et al. Obesity Reviews
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
- (2022) Mikhail N. Kosiborod et al. DIABETES OBESITY & METABOLISM
- Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
- (2022) Ildiko Lingvay et al. Obesity
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
- (2021) Tiffany M. Powell-Wiley et al. CIRCULATION
- GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Basedz Therapies in Treating Metabolic Disorders
- (2021) Ricardo J. Samms et al. DIABETES
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Obesity in adults: a clinical practice guideline
- (2020) Sean Wharton et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease
- (2020) Michael C. Honigberg et al. JAMA Cardiology
- Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: A systematic review and meta‐analysis of prospective cohort studies
- (2020) Jacob Opio et al. Obesity Reviews
- Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
- (2019) Zachary J. Ward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity
- (2018) Sadiya S. Khan et al. JAMA Cardiology
- Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis
- (2017) Chenhan Ma et al. BMJ-British Medical Journal
- Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis
- (2017) Chenhan Ma et al. BMJ-British Medical Journal
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis
- (2015) Nathalie Eckel et al. European Journal of Preventive Cardiology
- Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials胰高血糖素样肽-1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析
- (2014) Fang Zhang et al. Journal of Diabetes
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
- (2013) David C. Goff et al. CIRCULATION
- Predictors of Health-Related Quality of Life in Patients at Risk for Cardiovascular Disease in European Primary Care
- (2011) Sabine Ludt et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started